Enace

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enace

Understanding Enace

Enace is a medication belonging to the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily used to manage conditions related to the cardiovascular system, specifically high blood pressure (hypertension) and certain types of heart failure.

How It Works

The medication functions by interfering with the body's production of angiotensin II, a naturally occurring substance that causes blood vessels to tighten and narrow. By inhibiting the enzyme responsible for creating this substance, the medication allows blood vessels to relax and widen. This process results in lower blood pressure and makes it easier for the heart to pump blood to the rest of the body.

Primary Uses

  • Hypertension: It is used to lower elevated blood pressure, which helps reduce the workload on the heart and arteries over time.
  • Heart Failure: It may be used in the management of heart failure to help improve the heart's pumping efficiency and manage symptoms.
  • Post-Myocardial Infarction: In some cases, it is utilized following a heart attack to help improve survival rates and reduce the strain on the heart muscle.

Therapeutic Goals

The main objective of treatment with this medication is to maintain stable blood pressure levels and support overall cardiovascular function. By managing these conditions, the medication helps to protect vital organs, such as the kidneys and the heart, from the long-term effects of high blood pressure.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information

What side effects are possible with Enace?

Possible Side Effects and Safety Information: Enace

Enace (enalapril), an Angiotensin-Converting Enzyme (ACE) inhibitor, is generally well-tolerated, but like all medicines, it can cause side effects. Most side effects are mild and transient, but some require immediate medical attention.


Common Side Effects

Side effects that are relatively common and usually mild include:

  • Dry, Persistent Cough: This is a well-known side effect of ACE inhibitors, typically non-productive, and may resolve after stopping the medication.
  • Dizziness and Lightheadedness: This can occur, particularly when first starting treatment or after a dose increase, due to lowered blood pressure. Slowly rising from sitting or lying positions can help.
  • Headache and Fatigue/Weakness.

Serious Safety Information and Rare Side Effects

Consult a healthcare professional immediately if you experience any of the following serious side effects:

Serious Side Effect Description
Angioedema Swelling of the face, lips, tongue, or throat, which can cause difficulty breathing or swallowing. This is a rare but life-threatening allergic reaction.
Hyperkalemia High potassium levels in the blood, which can cause an abnormal heart rhythm. Regular blood tests are needed to monitor this.
Severe Hypotension Excessive drop in blood pressure leading to fainting (syncope) or severe dizziness.
Kidney/Liver Problems Signs of kidney impairment (e.g., change in urination) or liver issues (e.g., yellowing of the skin or eyes).

Contraindications and Warnings

Pregnancy: Enace should not be used during pregnancy, especially during the second and third trimesters, as it can cause serious harm to the fetus. Immediately inform your doctor if you become pregnant while taking this drug.

Interactions: Tell your doctor about all other medications and supplements you take, particularly potassium-sparing diuretics, potassium supplements, and Nonsteroidal Anti-inflammatory Drugs (NSAIDs), as these can increase the risk of hyperkalemia or compromise kidney function.

Overdose and Emergency Response

The official prescribing information defines the risks and required actions associated with over-ingestion of Enalapril maleate (Enace). Immediate medical attention must be sought for any suspected or confirmed overdosage.

Documented Overdose Manifestations and Risks

Feature Official Regulatory Statements
Documented Manifestations The primary clinical sign of overdose is profound hypotension (excessive low blood pressure), often resulting in severe dizziness, lightheadedness, and syncope (fainting). Other effects may include tachycardia or bradycardia.
Life-Threatening Outcomes Severe consequences documented in regulatory labels include stupor, acute renal failure, and hyperkalemia (elevated serum potassium levels). In high-risk patients, profound hypotension may lead to myocardial infarction or cerebrovascular accident.

Required Emergency Actions

Immediate medical help is required for any suspected overdose. Emergency services should be contacted if symptoms are severe, such as loss of consciousness or difficulty breathing. No specific antidote is known for Enalapril maleate. The active metabolite is dialyzable and can be removed from the bloodstream using hemodialysis.

Management is primarily symptomatic and supportive. The regulatory procedure includes placing the patient in a supine position and administering intravenous infusion of normal saline to correct volume depletion and stabilize blood pressure. Continuous monitoring of blood pressure, serum electrolytes, and renal function is required during hospital observation.

Therapeutic Uses of Enace

What Enace treats: main uses and benefits

Enalapril is a medication used in situations involving certain distressing symptoms linked to the cardiovascular system. There are three primary therapeutic areas for its use. The medicine is applied in addressing patients with hypertension (high blood pressure), symptomatic heart failure, and asymptomatic left ventricular dysfunction to manage related symptoms.

This approach is relevant when supportive symptom management is appropriate, as Enalapril assists with maintaining functional stability and easing the overall symptom burden. It is often used in clinical settings that involve acute or unstable symptom patterns, contributing to improved comfort during periods of heightened symptoms. The medication provides supportive relief when symptoms interfere with routine activities. As a general guide for patient perspective:

“Enalapril may be part of symptomatic management to help ease the physiological burden associated with chronic cardiovascular conditions.”

Quick Fact: Relief for Symptoms linked to organ-specific functional stress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Enace? — Official Regulatory Information

The eligibility profile for Enace (Enalapril maleate) is strictly defined by government regulatory documents, categorizing use by contraindications and conditional restrictions.


Eligibility Scope

  • Populations for whom use is allowed: Adults; Pediatric patients who are older than one month of age for the treatment of hypertension.
  • Populations for whom use is contraindicated: Patients with a history of angioedema related to any ACE inhibitor, or those with hereditary angioedema. Use is absolutely prohibited during the second and third trimesters of pregnancy. Enace must not be co-administered with Sacubitril/Valsartan or with Aliskiren in patients with diabetes or severe renal impairment.
  • Age-related eligibility rules: Use is not recommended in neonates (infants leq 1 month) or in pediatric patients with severe renal impairment (GFR <30 mL/min/1.73 m^2).
  • Condition-specific eligibility rules: Use is restricted and requires special precautions for patients with hepatic impairment, renal impairment, or certain cardiovascular obstructions (e.g., aortic stenosis).
  • Pregnancy and lactation eligibility status: Contraindicated in the second and third trimesters; use is not recommended during the first trimester or while breastfeeding.

Resulting Eligibility Structure

Regulatory documents define who can and cannot use Enace by establishing mandatory exclusions based on hypersensitivity history, physiological status, and specific concurrent drug therapies. Conditional eligibility applies to patient populations with pre-existing organ function limitations, which require special precautions as officially documented.

What should I know about interactions with other medicines?

The official regulatory profile for Enace is defined by prohibitions and warnings regarding co-administered substances, focused on managing hyperkalemia risk and avoiding severe reactions. The information below details the officially documented interaction patterns.

Interaction Category Specific Restriction or Outcome
Prohibited Combinations Co-administration with Sacubitril/Valsartan is formally contraindicated. A mandatory 36-hour wash-out period is required when switching between this medicine and Enace. The use of Aliskiren is also contraindicated in patients with diabetes mellitus or those with renal impairment (GFR < 60 mL/min/1.73 m²).
Potassium-Related Agents Co-administration of Enace with Potassium-Sparing Diuretics (e.g., spironolactone) or Potassium Supplements is officially documented to carry an increased risk of hyperkalemia. This risk is noted to be heightened in patients with impaired renal function.
Pharmacodynamic Effects The combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is documented to reduce the antihypertensive effect of Enace. Other antihypertensive agents and alcohol consumption are noted to enhance the hypotensive effect. Substances such as mTOR inhibitors and Racecadotril are formally listed as increasing the risk of angioedema.
Drug Exposure Alteration Concomitant use with Lithium is reported in official labeling to increase serum lithium concentrations due to reduced clearance, resulting in documented exposure modification.
Food and Timing Regulatory data confirms that food does not affect the bioavailability of Enace. Apart from the mandatory 36-hour separation for the contraindicated combination, no other timing rules are specified.

Mechanism of Action

Enace is an angiotensin-converting enzyme (ACE) inhibitor. Following oral administration, the prodrug enalapril undergoes hepatic hydrolysis to form its active metabolite, enalaprilat. Enalaprilat acts as a competitive antagonist, binding to and inhibiting the ACE metallopeptidase, which is distributed across various tissues, including the pulmonary endothelium.

This inhibition blocks the enzymatic conversion of angiotensin I to the potent vasoconstrictor, angiotensin II, within the renin-angiotensin-aldosterone system (RAAS) pathway. The resulting decrease in circulating angiotensin II concentrations leads to a downstream reduction in its signaling through the angiotensin II type 1 (AT1) receptor. Simultaneously, ACE is identical to kininase II, the enzyme responsible for degrading the vasodilator peptide bradykinin. Inhibition of ACE therefore also leads to elevated systemic bradykinin levels. The ultimate system-level physiological consequences are a reduction in vascular resistance via vasodilation and a decrease in aldosterone secretion, which modulates sodium and water retention.

Dosage and Administration Information

How Enace is Used: Official Administration and Dosing Principles

This section outlines the usage instructions for Enace (Enalapril maleate), detailing the administration route, standard dosing, and specific adjustments.

Administration and Dosage Forms

Enace is administered via the oral route, available as an oral tablet (in strengths like 2.5 mg, 5 mg, 10 mg, and 20 mg) and an oral solution. The medicine can be taken with or without food as the presence of food does not significantly affect its absorption.

Standard Adult Dosing and Frequency

Dosing is individualized and initiated at a low dose, then gradually increased (titrated) based on the patient's condition and tolerance. The frequency and range vary by indication:

Indication Starting Dose (Oral) Maximum Daily Dose (Oral) Dosing Frequency
Hypertension Typically 5 mg once daily 40 mg Once daily
Symptomatic Heart Failure 2.5 mg twice daily 40 mg (in two divided doses) Twice daily

For hypertension, if the blood pressure effect diminishes near the end of the day, the total daily dose may be divided into two administrations.

Population-Specific Adjustments

Dose reductions are utilized for patients with impaired renal function, which are implemented under medical supervision:

  • Renal Impairment: For patients with moderate to severe renal impairment (Creatinine Clearance less than or equal to 30 mL/min), the recommended initial daily dose is 2.5 mg.
  • Dialysis Patients: The initial dose is 2.5 mg on the day of dialysis, administered after the procedure. Dosing on non-dialysis days is adjusted based on response.

Enace is intended for chronic, long-term management of the approved conditions, with initial doses for heart failure requiring medical monitoring to assess patient response.

Recent Clinical Evidence

Recent Clinical Evidence

Core Study Findings

Research has focused on the study compound's properties and activity as they relate to inflammation. Pre-clinical and early-phase human trials examined whether an association was observed with joint function and mobility, and whether it influences pain in subjects.

In the context of acute flare-ups, research has explored the effect on symptom onset. A randomized controlled trial (RCT) reported findings related to a measured change in biomarkers of inflammation. Other trials have examined the clinical outcomes across various age groups and disease severities.


Tolerability and Comparative Data

Research has explored how the compound was handled by various patient populations. Studies reported observed tolerability issues, including minor gastrointestinal and neurological events, with monitoring of potential long-term effects being noted. Long-term data reported on the tolerability of the compound during extended use. It is not yet clear whether the long-term use has an impact on cardiovascular or renal function; research in these areas is ongoing.

Studies have evaluated whether the combination influences absorption when the drug is studied alongside a common anti-inflammatory compound. Results have compared the outcomes against older treatments that target similar biological pathways. Preliminary data provided initial results on its potential application in initial treatment contexts, but further large-scale trials are currently underway to explore these findings.

Frequently Asked Questions (FAQ)

Common questions about Enace (FAQ)

Q: How long does it typically take for Enace to start lowering blood pressure?

A: Official regulatory documents indicate that the blood pressure-lowering effect typically begins within one hour of taking an oral dose, with the maximum effect usually occurring within three to four hours. However, the complete, stable antihypertensive response may take several weeks of consistent daily treatment to achieve.

Q: What are the most common initial side effects people report when starting Enace?

A: Common side effects, particularly when starting treatment, include a dry cough, dizziness or lightheadedness, headache, and a feeling of fatigue or weakness. Official product information notes that these effects are often mild and may be transient.

Q: What should I avoid eating or drinking while taking Enace?

A: Official warnings note that taking potassium supplements or using salt substitutes that contain potassium may increase the risk of high potassium levels (hyperkalemia). These should be avoided unless specifically recommended by a healthcare provider. Regulatory documents also note that the combination with alcohol consumption is documented to enhance the hypotensive (blood pressure-lowering) effect.

Q: What are the signs of a serious allergic reaction to Enace that I should watch for?

A: The most serious allergic reaction is angioedema, which involves swelling of the face, lips, tongue, or throat. General signs can also include a rash, hives, itching, or difficulty breathing or swallowing. If signs of a serious reaction, like swelling or difficulty breathing, occur, immediate medical evaluation is necessary.

Q: Will taking Enace affect my ability to drive or operate machinery?

A: Since Enace can cause side effects such as dizziness or lightheadedness, especially when treatment is initiated, caution is generally advised. Because these effects can impair judgment, individuals should be cautious when driving or operating complex machinery until they are aware of their response to the medication.

Q: What is the purpose of the different strengths/dosages of Enace?

A: Enace is available in various strengths (e.g., tablet forms) to allow for individualized dosing. The specific condition being treated (such as high blood pressure versus heart failure) and the patient's physiological response determine the necessary strength. The availability of different strengths supports the required method of gradual dose adjustment (titration) as determined by a healthcare professional.

Q: How is Enace eliminated from the body?

A: According to official pharmacological data, Enace is converted in the body to its active form, enalaprilat, which is then eliminated primarily through the kidneys (renal excretion). Most of the administered dose is recovered in the urine and feces.

Q: Can Enace be used to protect the kidneys in people with diabetes?

A: Official clinical studies have explored the effect of Enace on the kidneys. In some patients with renal disease, including those with diabetes, the compound has been shown to cause decreases in the amount of protein in the urine, a measure related to kidney function.

Q: Can I stop taking Enace if my blood pressure returns to normal?

A: Enace is generally intended for chronic, long-term management of the approved conditions. Discontinuing the medicine, even if blood pressure appears normal, should be done only under the direction of a healthcare professional. Stopping the treatment may cause blood pressure to return to high levels.

Q: Can Enace cause any changes to my sense of taste?

A: Taste disturbance, sometimes called dysgeusia, is a recognized adverse event associated with the ACE inhibitor drug class to which Enace belongs. The potential for this side effect is noted in regulatory and official product information.

Q: Is Enace considered a common first-line treatment for high blood pressure?

A: Enace belongs to the ACE inhibitor class, which is widely recognized as a primary class of antihypertensive agents. It is a common first-line option used by healthcare providers for blood pressure reduction and cardiovascular stabilization.

Q: What is the mechanism by which Enace helps reduce the workload on the heart?

A: By inhibiting a specific enzyme in the body, Enace causes the blood vessels to relax and widen, a process called vasodilation. This reduction in resistance within the circulatory system effectively lessens the effort required by the heart to pump blood, thereby reducing the heart's workload.

Q: What are the signs that Enace might not be working for me?

A: Signs that the medication may not be exerting the full therapeutic effect would be the persistence or worsening of the condition’s symptoms. This could include consistently high blood pressure readings or worsening signs of heart failure, such as increased shortness of breath or swelling (edema).

Q: Can Enace interact negatively with over-the-counter pain relievers like ibuprofen?

A: Yes, official labeling warns of an interaction between Enace and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen. This combination may reduce the blood pressure-lowering effect of Enace and could increase the risk of impaired kidney function, particularly in volume-depleted or elderly patients.

Q: Can older adults generally use Enace safely?

A: Eligibility for Enace is determined primarily by physiological health rather than age alone. Dosage adjustment is officially recommended for all patients with impaired renal function (kidney issues). When used in populations with pre-existing organ function limitations, regulatory documents specify that use requires close medical supervision.

Q: Is Enace known to cause dizziness or lightheadedness, and how can I manage that?

A: Yes, dizziness and lightheadedness are common side effects, especially when first starting the medicine, due to the reduction in blood pressure. The official product information suggests that slowly rising from a sitting or lying position can help minimize this effect.

Q: Can Enace cause swelling in the hands or feet?

A: A rare but very serious side effect is Angioedema, which involves swelling of the face, lips, tongue, or throat. Official labeling indicates this swelling can also affect the extremities (arms and legs), including the hands and feet. This type of severe reaction necessitates immediate medical evaluation.

Q: How quickly do the side effects of Enace usually go away after stopping the drug?

A: The persistent dry cough associated with ACE inhibitors is noted in regulatory documents to resolve after stopping the medication. The time it takes for side effects to completely disappear is variable, but resolution may occur within days or take up to a month.

Q: What is the experience of switching from a different blood pressure medicine to Enace?

A: Regulatory documents explicitly warn that switching from Sacubitril/Valsartan (a combination heart failure drug) to Enace is contraindicated and requires a mandatory 36-hour break (wash-out period) between the last dose of one and the first dose of the other to prevent a serious reaction called angioedema.

Q: Is it normal to feel tired when first starting Enace?

A: Yes, fatigue and weakness are listed in official product information as common side effects that can occur when first beginning treatment with Enace. This effect is often mild.

Q: What happens if I stop taking Enace suddenly?

A: Studies show that abruptly stopping the active metabolite of Enace does not typically cause a rapid, rebound increase in blood pressure. However, because the medicine is used for long-term management, stopping suddenly may result in the loss of therapeutic benefit, leading to a return of high blood pressure or worsening of heart failure symptoms.

How should Enace be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines for the storage and disposal of this medication emphasize maintaining the drug's integrity and ensuring public safety. All statements below are based on general, government-verified best practices for prescription medicines when product-specific information is not detailed.

Feature Requirement (Based on Regulatory Standards)
Storage Temperature Store generally at controlled room temperature (15 C to 30 C / 59 F to 86 F).
Protection Keep in the original container and protect from excessive heat and moisture.
Child Safety Keep medication up and away, out of the reach and sight of children.
Disposal Prioritize authorized drug take-back programs. If unavailable, mix the substance with an inedible material, seal it in a container, and discard it with household trash. Do not use expired medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enace found in:

A-Z Index: